Compared to Yervoy, Merck’s Â Keytruda improved cancer survivalÂ
Merck drug Keytruda is hogging the limelight right now across the world. In medical fraternity, especially among the cancer specialists, this drug is the most talked about at the moment.
The drug, Keytruda, that has been developed by none other than Merck & Co. is useful in not one cancer conditions, but against three different types of cancer.
Latest reports suggest that Merck drug Keytruda is actually affective against three cancer conditions including melanoma, lung cancer and mesothelioma. The findings of three different studies in this regard were presented earlier today at the American Association for Cancer Research conference in Philadelphia.
In case of Melanoma, the study suggests that Merck came out with first head-to-head comparison of two approved “immune checkpoint inhibitors,” its Keytruda and Yervoy, as initial therapy for patients with advanced melanoma. Study suggests that compared to Yervoy, Keytruda improved survival without cancer worsening by 42 percent after 6 months and boosted overall survival more than 30 percent after a year. it is needless to say that this is a worthwhile improvement in the condition of cancer patients. The study further suggests that about 33 percent of patients on Keytruda responded, meaning their tumors shrank or disappeared, versus 12 percent getting Yervoy. Serious side effects occurred a bit sooner and more commonly in the Yervoy group.
When it comes to the lung cancer, Merck actually tested Keytruda in patients with advanced non-small cell lung cancer. The study claims that on average, patients survived for 12 months, including nearly 4 months without the cancer worsening, and 20 percent responded, meaning their tumors shrank or disappeared.